Literature DB >> 17109504

Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity.

Su-Ping Sun1, Ya-Zhou Liu, Tao Ye, Wen Zhang, Wen-Bin Shen, Jing-Lei Shi, Hai-Ting Xu, Wei-Dong Wang.   

Abstract

AIM: Tumor response and normal tissue toxicity of seven-day-per-week continuous accelerated irradiation (CAIR) for patients with esophageal carcinoma were evaluated and compared to conventional irradiation (CR).
METHODS: Sixty patients with squamous cell carcinoma of the esophagus were randomized into two groups: the CAIR group (30 patients) and the CR group (30 patients). Patients in the CAIR group received radiotherapy (RT) with 2 Gy/fraction per day at 7 d/wk with a total dose of 50-70 Gy (average dose 64.2 Gy). The overall time of irradiation was 3.6-5.0 wk (average 4.6 wk). RT in the CR group was 2 Gy/fraction per day at 5 d/wk with a total dose of 40-70 Gy (average dose 61.7 Gy). The overall time of irradiation was 4.0-7.0 wk (average 6.4 wk).
RESULTS: The data showed that the immediate tumor response to RT was better in the CAIR group than in the CR group. Efficiency rates (CR plus PR) were 82.8% (24/29) and 58.6% (17/29), respectively (P = 0.047). In both groups the incidences of esophagitis and tracheitis were insignificant (P = 0.376, 0.959), and no patient received toxicity that could not be tolerated.
CONCLUSION: CAIR shortens overall treatment time and is well tolerated by patients. It may be superior to CR in enhancing the local response of tumor, but its remote effect for esophageal carcinoma awaits further follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109504      PMCID: PMC4087353          DOI: 10.3748/wjg.v12.i43.7047

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report.

Authors:  A C Begg; I Hofland; L Moonen; H Bartelink; S Schraub; P Bontemps; R Le Fur; W Van Den Bogaert; R Caspers; M Van Glabbeke
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-12       Impact factor: 7.038

2.  Late course accelerated hyperfractionated radiotherapy for clinical T1-2 esophageal carcinoma.

Authors:  Kuai-Le Zhao; Yang Wang; Xue-Hui Shi
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

3.  Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.

Authors:  K Skladowski; B Maciejewski; M Golen; B Pilecki; W Przeorek; R Tarnawski
Journal:  Radiother Oncol       Date:  2000-05       Impact factor: 6.280

Review 4.  Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer.

Authors:  M Baumann; S Appold; C Petersen; D Zips; T Herrmann
Journal:  Lung Cancer       Date:  2001-09       Impact factor: 5.705

Review 5.  Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck.

Authors:  William M Mendenhall; Charles E Riggs; Robert J Amdur; Russell W Hinerman; Douglas B Villaret
Journal:  Laryngoscope       Date:  2003-03       Impact factor: 3.325

6.  Late-course accelerated hyperfractionated radiotherapy for localized esophageal carcinoma.

Authors:  Kuai-Le Zhao; Xue-Hui Shi; Guo-Liang Jiang; Yang Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

7.  From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.

Authors:  S M Bentzen; M I Saunders; S Dische
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-10       Impact factor: 4.126

8.  Comparison between continuous accelerated hyperfractionated and late-course accelerated hyperfractionated radiotherapy for esophageal carcinoma.

Authors:  Yang Wang; Xue-Hui Shi; Shao-Qin He; Wei-Qiang Yao; Yin Wang; Xiao-Mao Guo; Gen-Di Wu; Long-Xiang Zhu; Tai-Fu Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-09-01       Impact factor: 7.038

9.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation.

Authors:  H K Awwad; M Lotayef; T Shouman; A C Begg; G Wilson; S M Bentzen; H Abd El-Moneim; S Eissa
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more
  2 in total

1.  Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma.

Authors:  K Fakhrian; M Oechsner; S Kampfer; T Schuster; M Molls; H Geinitz
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

2.  Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Yingyu Liu; Changgui Kou; Yingying Su; Yangyu Zhang; Yueyue You; Lili Zhang; Mohan Wang; Yingli Fu; Xiaojun Ren; Yanming Yang
Journal:  Onco Targets Ther       Date:  2017-06-13       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.